Figures & data
Table I. Baseline demographics and clinical characteristics.
Figure 1. Overall survival (A) and progression-free survival (B) in patients receiving combination chemotherapy with or without bevacizumab.
![Figure 1. Overall survival (A) and progression-free survival (B) in patients receiving combination chemotherapy with or without bevacizumab.](/cms/asset/57d96df6-50b0-49ba-b504-156820eef429/ionc_a_958532_f0001_b.gif)
Table II. Outcomes in patients receiving combination chemotherapy with or without bevacizumab.
Figure 2. Overall survival (A) and progression-free survival (B) in patients receiving irinotecan-based chemotherapy with or without bevacizumab.
![Figure 2. Overall survival (A) and progression-free survival (B) in patients receiving irinotecan-based chemotherapy with or without bevacizumab.](/cms/asset/5d17d55b-389a-499f-9a0f-0d2f3160000c/ionc_a_958532_f0002_b.gif)
Figure 3. Overall survival (A) and progression-free survival (B) in patients receiving bevacizumab therapy with oxaliplatin/irinotecan.
![Figure 3. Overall survival (A) and progression-free survival (B) in patients receiving bevacizumab therapy with oxaliplatin/irinotecan.](/cms/asset/bdff8677-f7e5-4769-8aa3-8b9dbb69ec40/ionc_a_958532_f0003_b.gif)
Table III. Outcomes in patients receiving irinotecan-based chemotherapy backbone.
Table IV. Bevacizumab treated patients’ outcomes, according to the chemotherapy backbone.